Acer Therapeutics Inc

Acer Therapeutics — Opexa Therapeutics — Investor Presentation (February 2013)

20 slides from Acer Therapeutics's investor presentation, Feb 11, 2013

  1. Slide 1: Opexa Therapeutics, Inc. Precision Medicine

    Opexa Therapeutics, Inc. Precision Medicine February 2013 Neil Warma President & CEO

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “expects,” “believes,” “may,” “could,” “potential” and

  3. Slide 3: Opexa Highlights

    Opexa Highlights Opexa is one of the leading cellular therapy companies – Focused on developing TcelnaTM, a T-cell immunotherapy for Multiple Sclerosis (MS) Currently conducting a Phase IIb clinical trial in Secondary Progressive MS (SPMS) – Fast Track designation granted by FDA February 5, 2013 ann

  4. Slide 4: Personalized Medicine: Autologous Cell Therapy

    Personalized Medicine: Autologous Cell Therapy Stem-cell Platform Multiple Sclerosis Additional Autoimmune Diseases - Preclinical stage Tcelna in Phase IIb development for SPMS T-cell Platform Type 1 Diabetes - Potential exists to expand in other indications T-cell platform: Every dose is personaliz

  5. Slide 5: Pipeline and Potential Areas of Investigation

    Pipeline and Potential Areas of Investigation Stage of Development * Rights granted to Merck Serono under option and license agreement (Feb. 5, 2013)

  6. Slide 6: MRTCs' Role in Multiple Sclerosis

    MRTCs’ Role in Multiple Sclerosis MRTC In MS patients, the faulty immune system is not able to prevent the attack of a small sub-population of myelin reactive T-cells (MRTCs)Opexa’s strategy is to inject a large therapeutic bolus of attenuated MRTCs back into the patientImportant to Opexa’s Strategy

  7. Slide 7: Tcelna Manufacturing

    Tcelna™ Manufacturing (Gp:) Expansion of antigen specific T-cells (Gp:) Cryopreservation (Gp:) Formulation/Irradiation of each dose as required (Gp:) Epitope profiling (Gp:) Administration: 5 subcutaneous injections/year (Gp:) Manufacturing and QC (Gp:) Dispensation (Gp:) 35 days (Gp:) Epitope Profi

  8. Slide 8: Safety and Tolerability Overview

    Safety and Tolerability Overview To date, Tcelna has demonstrated superior safety to MS drugs marketed and in developmentTcelna is very well tolerated with favorable safety profileNo Serious Adverse Events (SAE) associated with treatment in previous Phase IIb Relapsing Remitting MS (RRMS) clinical t

  9. Slide 9: Tcelna Clinical and Regulatory Overview

    Tcelna Clinical and Regulatory Overview Five Phase I and Phase II clinical trials have been conducted to date with Tcelna in both RRMS and SPMS patientsOver 300 subjects have been enrolled in these trials with over 140 being treated with TcelnaEncouraging signs of clinical efficacy observed in both

  10. Slide 10: Tcelna Efficacy Data Overview

    Tcelna Efficacy Data Overview Phase IIb trial in RRMS: U.S. trial in 150 patients Strong clinical signal : 37% reduction in Annualized Relapse Rate (ARR) vs. placeboARR = 0.21 vs. 0.34 (on par with existing marketed drugs)77% relapse free in Tcelna groupSub population of more active patients from Ph

  11. Slide 11: Opexa's Focus: Filling the Void in SPMS Treatment

    Opexa’s Focus: Filling the Void in SPMS Treatment Over 1 million people affected by SPMS worldwide… …only ONE FDA approved product for SPMS (Gp:) SPMS (Gp:) Tcelna™ (Gp:) Novantrone Limited use due to Black Box warning added to Novantrone’s prescribing information by the FDA in April 2005 There are

  12. Slide 12: Abili-T: Landmark trial in SPMS

    Abili-T TM : Landmark trial in SPMS Abili-T Phase IIb clinical trial in SPMS is ongoingDouble-blind, 1:1 randomized, placebo-controlledEnthusiasm among MS community (patients and sites) is highApproval by Health Canada enables expansion into Canada180 PatientsSPMS population30 sites in USA and Canad

  13. Slide 13: Opexa's Immune Monitoring Program Overview

    Opexa’s Immune Monitoring Program OverviewOpexa is undertaking a comprehensive Immune Monitoring Program to capture valuable information from the Abili-T trial in SPMS patientsThe Immune Monitoring Program will harvest multiple samples from 180 SPMS patients over two years and will be analyzed in re

  14. Slide 14: Option and license agreement with Merck Serono

    Opexa secures option and license agreement with Merck Serono for MS indication Option and License agreement jointly announced February 5, 2013Total potential payments to Opexa up to $225 million$5 million upfront option grant fee$25 million, or $15 million, option exercise feeUp to $195 in developme

  15. Slide 15: Value for Opexa

    Value for Opexa If option is exercised, potential payments to Opexa up to $225 million over next several years and beyond plus tiered royalties based on net salesAlliance with one of the leading global Pharma companies with commitment, franchise and expertise in MSPath to commercialization of Tcelna

  16. Slide 16: Expected Development Timeline

    Expected Development Timeline Option and license agreement with Merck Serono(up to option exercise) SPMS Phase II clinical trial 1H ‘13 2H ‘13 1H ‘14 2H ‘14 1H ‘15 2H ‘15 2H ‘12 $5 M upfront option fee Option exercise period Top line data Full analysis (180 subjects) Pipeline Development Biomarker s

  17. Slide 17: Milestones and Goals

    Milestones and Goals Obtained FDA Fast Track approval for Tcelna™ in SPMS (Q4’11 )Initiated “Abili-T” 180 patient Phase IIb SPMS clinical trial in U.S. (Q3’12)Closed option and license agreement with Merck Serono, global leader in MS (Q1’13) Secured $3.25 million in private offering (Q1’13)Evaluate

  18. Slide 18: Financial Highlights

    Financial Highlights Basic Shares Outstanding ~7.9 M Fully Diluted ~14.8 MMarket Capitalization ~$20 M52 week range $1.07-$5.19Monthly Burn $885,000Cash Position $2.2 M (at 9/30/12 per Q3 Earnings Release) $5 M (upfront option fee 2/5/13 option agreement) $3.25 M (gross proceeds from private placeme

  19. Slide 19: Opexa Highlights

    Opexa Highlights Developing one of most promising therapies for Multiple SclerosisPersonalized, patient specific, with encouraging clinical efficacy and superior safety profileSecured option agreement for Tcelna in MS with leading global Pharma company (potential payments up to $225 M + royalties)Ke

  20. Slide 20: Opexa: Developing Novel Treatments for Cell Therapy

    Opexa: Developing Novel Treatments for Cell Therapy

Opexa Therapeutics — Investor Presentation (February 2013) on 6ix